Difference between revisions of "Lobaplatin (D-19466)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 5: Line 5:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
 
==Clinical trials==
 
<br>
 
  
 
==Also known as==
 
==Also known as==
1,2-diammino-methy lcyclobutane-platinum (II) lactate, D-19466
+
*'''Code name:''' D-19466
  
 
==References==
 
==References==
Line 16: Line 13:
  
 
[[Category:Drug index]]
 
[[Category:Drug index]]
[[Category:Chemotherapy]]
 
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Platinum agents]]
 
[[Category:Platinum agents]]
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
[[Category:Investigational]]
+
[[Category:CFDA approved drugs]]

Revision as of 02:24, 29 November 2017

General information

Class/mechanism: Third-generation platinum compound with DNA alkylating activity, producing interstrand DNA crosslinks, which result in apoptosis.[1]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Also known as

  • Code name: D-19466

References